Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial

PURPOSE: In the phase III METEOR trial (ClinicalTrials.gov identifier: NCT01865747), 658 previously treated patients with advanced renal cell carcinoma were randomly assigned 1:1 to receive cabozantinib or everolimus. The cabozantinib arm had improved progression-free survival, overall survival, and...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Clin Oncol
Κύριοι συγγραφείς: Cella, David, Escudier, Bernard, Tannir, Nizar M., Powles, Thomas, Donskov, Frede, Peltola, Katriina, Schmidinger, Manuela, Heng, Daniel Y.C., Mainwaring, Paul N., Hammers, Hans J., Lee, Jae Lyun, Roth, Bruce J., Marteau, Florence, Williams, Paul, Baer, John, Mangeshkar, Milan, Scheffold, Christian, Hutson, Thomas E., Pal, Sumanta, Motzer, Robert J., Choueiri, Toni K.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Clinical Oncology 2018
Θέματα:
ORIGINAL REPORTS
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6804841/
https://ncbi.nlm.nih.gov/pubmed/29377755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.75.2170
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια